Leptomeningeal Metastases Market Summary
The Leptomeningeal Metastases Market in the 7MM was valued at approximately USD 1,700 million in 2024, over the forecast period from 2025 to 2034. The Leptomeningeal Metastases market is projected to grow at a significant CAGR by 2034 across leading countries (US, EU4, UK, and Japan). Despite the substantial clinical burden, no therapies are currently approved specifically for leptomeningeal metastases, and management remains palliative and multimodal, relying on off-label systemic agents combined with radiation therapy. Pharmaceutical engagement in this space has largely remained limited to supportive roles, though notable exceptions such as Plus Therapeutics are now advancing dedicated, targeted radiotherapeutics, marking a pivotal shift in the treatment landscape.
Explore DelveInsight’s Full Coverage on the Leptomeningeal Metastases Market
Leptomeningeal Metastases Overview
Leptomeningeal metastases, also known as leptomeningeal carcinomatosis, neoplastic meningitis, carcinomatous meningitis, or leptomeningeal disease, represent a serious and often debilitating complication of advanced metastatic solid tumors. The condition refers to the dissemination of malignant cells into the leptomeninges (the pia and arachnoid mater) surrounding the brain and spinal cord, as well as into the cerebrospinal fluid (CSF). These cells disrupt normal CSF drainage pathways, resulting in fluid buildup and increased intracranial pressure, which causes headaches, balance issues, and cranial nerve-related weakness, numbness, or pain, often more prominent in the morning, along with nausea and vision problems.
Leptomeningeal metastases is frequently seen in breast, lung, or melanoma cancers, and typically stems from the progression of systemic cancers originating in the breast, lungs, gastrointestinal tract, hematologic system, melanoma, or the CNS. Several risk factors are associated with its development: in brain tumors, leptomeningeal metastases are more likely following surgical resection of parenchymal metastases, especially in the posterior fossa; in breast cancer, lobular histology and HER2-positive and triple-negative subtypes carry higher risk; and in non-small cell lung cancer (NSCLC), EGFR mutations and ALK translocations are associated with increased incidence.
Leptomeningeal Metastases Diagnosis and Treatment Algorithm
Diagnosing leptomeningeal metastases begins with a comprehensive review of the patient’s medical history and a detailed physical and neurological examination, which helps determine the extent of neurological involvement and raises suspicion for the disease. Once suspected, CSF analysis and neuroimaging become essential next steps. Tumor markers in CSF are valuable for early detection, monitoring treatment response, and predicting outcomes, including general markers like lactate dehydrogenase and beta-2 microglobulin, along with specific markers such as alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (ß-hCG), and carcinoembryonic antigen (CEA).
Since surgical excision is not a viable option due to the diffuse nature of the condition, management prioritizes symptom relief and disease control through a coordinated, multidisciplinary approach. Treatment usually begins with targeted radiation therapy to alleviate neurological symptoms, followed by systemic therapies capable of penetrating the central nervous system. In selected patients presenting with obstructive hydrocephalus, ventriculoperitoneal shunting (VPS) may provide effective palliation, with over 80% of patients reporting symptomatic improvement and a relatively low rate of complications; recent studies also indicate a potential survival benefit when VPS is combined with intrathecal therapy. A comprehensive treatment plan often integrates radiation therapy, conventional systemic therapies (such as methotrexate, cytarabine, temozolomide, capecitabine, topotecan, and lapatinib), intrathecal therapy, immunotherapy, and molecularly targeted treatments tailored to the patient and disease biology.
Leptomeningeal Metastases Market Players
Leptomeningeal Metastases companies include:
- Plus Therapeutics
- Angiochem
- Y-mAbs Therapeutics
- Kazia Therapeutics
- Genentech
- AstraZeneca
- M.D. Anderson Cancer Center (Collaborator: Treovir)
- Daiichi Sankyo
- Quadriga BioSciences
- And Others.
Leptomeningeal Metastases Epidemiology
The epidemiology section of the Leptomeningeal Metastases market insight report provides historical and projected patient population data across the seven major markets (7MM), segmented by total incident cases, incident cases by cancer type, incident cases by risk type, gender-specific cases, and treated patient pool. This section provides a robust understanding of disease burden across regions from 2020 to 2034.
Key Findings:
- In 2024, the Leptomeningeal Metastases Incident Cases were approximately 300,000 in the 7MM, reflecting a significant clinical burden
- The US showed the highest number of incident cases of leptomeningeal metastases, accounting for approximately 40% of the incident cases in the 7MM in 2024
- In 2024, the total Leptomeningeal Metastases Incident Cases were approximately 120,000 in the US
- In 2024, breast cancer recorded the highest incident cases of leptomeningeal metastases among all cancer types across EU4 and the UK, with approximately 30,000 cases reported
- In Germany in 2024, incident leptomeningeal metastases cases were stratified by risk classification, with 66% of patients falling under the “good risk” category and the remaining 34% categorized as “poor risk”
Leptomeningeal Metastases Market Outlook
The Leptomeningeal Metastases market trends point to continued expansion through the forecast period (2025–2034), driven by pipeline candidates such as Plus Therapeutics’ REYOBIQ (rhenium Re186 obisbemeda), Kazia Therapeutics/Genentech’s Paxalisib, and others. In 2024, the Leptomeningeal Metastases Market Size in the 7MM was approximately USD 1,700 million, which is expected to rise by 2034. In 2024, the US captured nearly 60% of the leptomeningeal metastases market, driven by extensive use of systemic, targeted, intrathecal, and radiotherapy-based interventions, supported by favorable reimbursement structures and rapid adoption of novel therapies. Among the EU4 and the UK, Germany had the highest Leptomeningeal Metastases Market Size in 2024 at approximately USD 160 million, followed by the UK at approximately USD 130 million.
Marketed Leptomeningeal Metastases Drugs
Currently, there are no therapies approved specifically for leptomeningeal metastases. Management remains palliative and multimodal, relying on a combination of off-label agents alongside radiation therapy:
Off-Label Systemic Agents
Methotrexate, cytarabine, temozolomide, capecitabine, topotecan, and lapatinib are used off-label in combination with radiation therapy to slow disease progression and maintain neurological function. Despite widespread use, this approach reflects a significant unmet need, as no agent has been specifically approved for the indication, and diagnosis is often delayed due to the lack of effective screening methods.
Download the Leptomeningeal Metastases market report for in-depth insights on pipeline and forecast
Emerging Leptomeningeal Metastases Drugs
The Leptomeningeal Metastases market size is expected to evolve significantly, supported by an active pipeline of emerging therapies addressing substantial unmet need. Key emerging candidates include REYOBIQ (rhenium Re186 obisbemeda), Paxalisib, QBS72S, and others, with active development programs targeting novel mechanisms and improved central nervous system penetration.
- REYOBIQ (rhenium Re186 obisbemeda) – Plus Therapeutics
REYOBIQ is an innovative injectable radiotherapy designed to deliver high-dose, targeted radiation directly to central nervous system tumors with a focus on safety, efficacy, and ease of administration. Leveraging the unique properties of rhenium-186, its short half-life, beta emissions for tumor destruction, and gamma emissions for real-time imaging, REYOBIQ offers a promising approach for CNS therapies. It is currently under evaluation for leptomeningeal metastases treatment in the ongoing ReSPECT-LM clinical trials.
In January 2026, Plus Therapeutics announced a successful Type B meeting with the FDA regarding REYOBIQ, with the FDA providing guidance on the design of a potential registrational Phase 2/3 trial
In July 2025, Plus Therapeutics announced it would unveil ReSPECT-LM clinical trial findings and lead a sponsored educational symposium at the SNO/ASCO CNS Metastases Conference (August 14–16, 2025)
In March 2025, the US FDA granted Orphan Drug Designation (ODD) to REYOBIQ for leptomeningeal metastases treatment in patients with lung cancer
- Paxalisib – Kazia Therapeutics/Genentech
Paxalisib (GDC-0084) is an experimental therapy under development for treating a range of brain cancers. It acts as a brain-penetrant inhibitor of the PI3K/Akt/mTOR signaling pathway, which plays a vital role in regulating cell growth and division, and is designed to cross the blood-brain barrier for efficient drug delivery to brain tissue.
In October 2024, at the 66th Annual Meeting of ASTRO, Kazia Therapeutics shared Phase I data showing a 45 mg dose of paxalisib combined with radiotherapy resulted in a 67% partial response rate in patients with brain or leptomeningeal metastases harboring PI3K mutations
In February 2024, Kazia Therapeutics reported the early conclusion of a clinical trial after successfully meeting its primary endpoint, with the combination of paxalisib and radiotherapy demonstrating encouraging potential for treating brain metastases associated with PI3K pathway mutations
- QBS72S – Quadriga BioSciences
QBS72S is a first-in-class therapy designed to mimic a large neutral amino acid to cross the blood-brain barrier via the LAT1 transporter.
In February 2026, Quadriga BioSciences announced encouraging interim Phase II results for QBS72S in breast cancer patients with leptomeningeal disease, with promising clinical activity and a manageable safety profile, suggesting that targeting the LAT1 pathway could be a breakthrough strategy for patients whose cancer has spread to the cerebrospinal fluid
Additional Pipeline Candidates
Additional early-stage candidates in interventional studies mentioning leptomeningeal metastases include HSV G207 (M.D. Anderson Cancer Center, in collaboration with Treovir), an oncolytic virus in Phase I for recurrent or refractory cerebellar brain tumors, and AZD1390 given with radiation therapy (AstraZeneca), a small molecule ataxia telangiectasia mutated protein inhibitor in Phase I for brain cancer. Antibody-drug conjugates such as Patritumab deruxtecan (Daiichi Sankyo) have also shown promising activity in treating leptomeningeal metastases. Angiochem’s ANG1005, a peptide-drug conjugate engineered to cross both the blood-brain and blood-CSF barriers, previously advanced in development, though its progress is currently stalled. Separately, Y-mAbs Therapeutics’ Omburtamab, a radiolabeled monoclonal antibody targeting B7-H3 in CNS tumors and leptomeningeal metastases, completed pivotal studies but received a Complete Response Letter (CRL) from the FDA in 2022 due to insufficient clinical benefit and concerns over study design.
Leptomeningeal Metastases Drugs Uptake
This section examines the sales uptake of potential leptomeningeal metastases drugs anticipated to launch during the forecast period, estimating market penetration across countries and evaluating their impact within and across therapeutic classes and segments. It also addresses the financial and regulatory factors contributing to the probability of success of drugs in the leptomeningeal metastases market.
Emerging therapies are analyzed on the basis of safety and efficacy in interventional clinical trials, order of market entry, broader market dynamics, and the degree to which they address the substantial unmet need within the leptomeningeal metastases treatment landscape, given that no therapies are currently approved specifically for this indication.
Conclusion
The Leptomeningeal Metastases market is poised for meaningful growth through 2034, supported by a significant disease burden, rising incidence of CNS metastases as patients live longer with advanced cancer, and continued advancements in therapeutic innovation. While management today remains palliative, relying on off-label systemic agents and radiation therapy, persistent unmet needs – particularly the absence of any approved, indication-specific therapy and the challenge of achieving adequate drug penetration across the blood-brain and blood-CSF barriers – are driving development of next-generation, targeted agents. Promising pipeline candidates such as REYOBIQ, Paxalisib, and QBS72S have the potential to reshape the treatment landscape and enhance patient outcomes. As research progresses and regulatory pathways advance, the Leptomeningeal Metastases market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term challenges associated with this aggressive and hard-to-treat condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
